Myocardial Injury After Noncardiac Surgery (MINS)VISION-2NCT07300579
Vascular Events in Noncardiac Surgery Patients Cohort Evaluation Study 2
An observational study of Myocardial Injury After Noncardiac Surgery (MINS) and Bleeding Independently Associated With Mortality After Noncardiac Surgery (BIMS), run by Hamilton Health Sciences Corporation at 3 sites in Canada.
Trial summary
VISION-2 is an international, multi-site, prospective observational cohort study of 20,000 patients undergoing noncardiac surgery. Continuous biometric data will be blindly collected for the first 30 postoperative days, in hospital and at home, using Vitaliti™. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Myocardial Injury After Noncardiac Surgery (MINS), Bleeding Independently Associated With Mortality After Noncardiac Surgery (BIMS), Sepsis
- What is being tested?
- Continuous vital signs measurement device
- Type of treatment
- Medical device
- How many people
- 20,000 participants
- Where
- 3 sitesCanada
- Study dates
- Jun 2026to Jun 2032
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: Patients 65 years of age and older undergoing non-cardiac surgery with anesthesia expected to require an expected length of hospital stay of 3 or more days
Who may be able to join
- age ≥65 years;
- underwent non-cardiac surgery with general, neuraxial, local, or regional anesthesia; and
- expected length of hospital stay of 3 or more days
Who cannot join
- hearing aid(s) or cochlear implant(s) in left ear;
- pacemaker/implantable cardioverter-defibrillator (ICD);
- externally programmable cerebrospinal fluid shunt;
- deep brain stimulator;
- intolerance/allergy to adhesive;
- history of dementia, or;
- previous enrollment in the VISION-2 Study
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Canada3 sites
Hamilton General Hospital
Hamilton, Ontario, L8L 2X2
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, L8N 4A6
Juravinski Hospital & Cancer Centre
Hamilton, Ontario, L8V 1C3
About this study
VISION-2 is an international, multi-site, prospective observational cohort study of 20,000 patients undergoing noncardiac surgery. Continuous biometric data will be blindly collected for the first 30 postoperative days, in hospital and at home, using Vitaliti™. Following study enrollment and baseline data collection, follow up visits will occur in-hospital, at 30-days, and 1-year post-operatively.
VISION-2 has 3 primary objectives, among participants who underwent noncardiac surgery, the investigators will: 1) determine the pattern and frequency of physiological precursors (i.e., biophysical signals) to MINS, BIMS, sepsis, and infection without sepsis; 2) build prediction models from these biophysical signals and their extracted features through supervised machine learning, for the prediction and early detection of those complications; and 3) build a biobank for evaluation of novel biomarkers.
- Conditions
- Myocardial Injury After Noncardiac Surgery (MINS), Bleeding Independently Associated With Mortality After Noncardiac Surgery (BIMS), Sepsis, Infection Without Sepsis, Post-operative Complications
- Being tested
- Continuous vital signs measurement device
- Medical subject headings
- Sepsis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Continuous vital signs measurement deviceDevice
In this observational study, enrolled participants will wear the Vitaliti™ CVSM-1A device continuously before surgery, wherever and whenever possible, or as soon as possible after surgery and for up to 30-days after surgery. We will collect continuous biometric data using the Vitaliti™ CVSM-1A device. Patients, healthcare providers, data collectors, and outcome adjudicators will be blind to the Vitaliti™ data. Data from participants will be analyzed to determine the pattern and frequency of physiological precursors to outcome events. This data will be used to inform machine learning algorithms for prediction and early detection of post-surgical complications. A biobank will also be established to support exploratory proteomic and genotyping analyses to better understand biological mechanisms underlying post-operative complications.
What is being measured
The primary outcome is the main question the study is designed to answer.
Myocardial injury after noncardiac surgery (MINS)
MINS not meeting 4th definition of MI is an elevated troponin measurement that occurs during the first 30 days after surgery that is judged as resulting from myocardial ischemia AND does not fulfill the MI definition. The following defines elevated troponin measurement for the diagnosis of MINS during the first 30 days after surgery: non high sensitivity Troponin T assay: ≥0.03 µg/L; high sensitivity Troponin T assay: between 20 - <65 ng/L with an absolute change ≥5 ng/L or a value ≥65 ng/L; DVIA Centaur Siemens high-sensitivity cardiac troponin I: ≥75 ng/L; ARCHITECT STAT Abbott Laboratories high-sensitivity cardiac troponin I ≥60 ng/L; other troponin assays: any measurement above the 99th percentile of the upper reference limit.
Measured: 30 days after surgery
Bleeding independently associated with mortality after noncardiac surgery (BIMS)
A bleeding meeting any of the following 3 criteria: a) leading to a postoperative hemoglobin <70 g/L; b) requiring transfusion of one or more units of red blood cells; c) judged to be the immediate cause of death
Measured: 30 days after surgery
Sepsis
Based on the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) criteria, sepsis will require a quick Sequential Organ Failure Assessment (qSOFA) Score ≥2 points due to infection. The qSOFA includes the following items and scoring system: a) Glasgow Coma Scale (GCS) score of 13 or less (1 point); b) systolic blood pressure of 100 mm Hg or less (1 point); and c) respiratory rate of 22 breaths/min or more (1 point).
Measured: 30 days after surgery
Infection without sepsis
Pathologic process caused by the invasion of normally sterile tissue or fluid or body cavity by pathogenic or potentially pathogenic organisms.
Measured: 30 days after surgery
Secondary outcomes (27)
All-cause mortality
Death by any cause
Measured: 30 days after surgery
Vascular mortality
Any death with a vascular cause and includes those deaths following a myocardial infarction, cardiac arrest, stroke, cardiac revascularization procedure (i.e., percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery), heart failure, pulmonary embolus, cardiovascular hemorrhage (i.e., hemorrhage causing cardiac tamponade, non-traumatic vascular rupture [e.g., aortic aneurism, cerebrovascular aneurism], non-stroke intracranial hemorrhage), or deaths due to an unknown cause.
Measured: 30 days and 1 year after surgery
Myocardial infarction (MI)
The definition of myocardial infarction follows the 4th universal definition
Measured: 30 days and 1 year after surgery
Stroke
An acute episode of neurological dysfunction consistent with an ischemic or hemorrhagic cause. For the diagnosis of stroke, the following criteria must be fulfilled: a) rapid onset of a focal/global neurologic deficit with at least one of the following: change in level of consciousness, hemiplegia, hemiparesis, numbness or sensory loss affecting one side of the body, dysphagia/aphasia, hemianopia, amaurosis, or other new neurological signs/symptoms consistent with stroke; b) the duration of a focal/global neurologic deficit is at least 24 hours, OR the neurological deficit results in death, OR there is neuroimaging evidence of a new infarct/ hemorrhage; and c) there is no other readily identifiable non-stroke cause for the clinical presentation (e.g., brain tumor, trauma, infection, hypoglycemia, peripheral lesion).
Measured: 30 says and 1 year after surgery
Proximal venous thromboembolism (VTE)
Proximal VTE includes pulmonary embolism or proximal deep vein thrombosis.
Measured: 30 days and 1 year after surgery
Proximal deep venous thrombosis (DVT)
The diagnosis of proximal deep venous thrombosis requires:
Thrombosis involving the popliteal vein or more proximal veins for leg DVT or axillary or more proximal veins for arm DVTs.
Any of the following defines evidence of vein thrombosis:
A persistent intraluminal filling defect on contrast venography (including on computed tomography), Noncompressibility of one or more venous segments on B mode compression ultrasonography, or a clearly defined intraluminal filling defect on doppler imaging in a vein that cannot have compressibility assessed (e.g., iliac, inferior vena cava, subclavian).
Measured: 30 days and 1 year after surgery
Pulmonary embolism (PE)
The diagnosis requires symptoms and any one of the following:
- a high probability ventilation/perfusion lung scan,
- an intraluminal filling defect of segmental or larger artery on a helical CT scan,
- an intraluminal filling defect on pulmonary angiography, or
- a positive diagnostic test for DVT (e.g., positive compression ultrasound) and one of the following:
- non-diagnostic (i.e., low or intermediate probability) ventilation/perfusion lung scan, or ii) non-diagnostic (i.e., subsegmental defects or technically inadequate study) helical CT scan
Measured: 30 days and 1 year after surgery
Acute kidney injury (AKI)
Increase in serum creatinine concentration from the preoperative (pre-enrollment) concentration by either an increase of ≥26.5 μmol/L (≥0.3 mg/dL) within 48 hours of surgery or an increase of 50% or greater within 7 days of surgery.
Measured: 30 days and 1 year after surgery
New acute renal failure resulting in dialysis
New acute renal failure resulting in use of a hemodialysis machine or peritoneal dialysis apparatus
Measured: 30 days and 1 year after surgery
Acute heart failure
Acute Heart Failure is defined as a clinical sign (i.e., at least one of the following: elevated jugular venous pressure, respiratory rales/crackles, crepitations, or presence of S3) and at least one of the following:
- Radiographic findings (i.e., at least one of the following: vascular redistribution, interstitial pulmonary edema, frank alveolar pulmonary edema, or multiple and diffuse bilateral B lines on ultrasonography);
- Elevated levels of natriuretic peptides; or
- Heart failure treatment implemented with diuretics with documented clinical improvement.
Measured: 30 days and 1 year after surgery
New clinically important atrial fibrillation
The definition of clinically important atrial fibrillation requires the documentation of atrial fibrillation of any duration on an ECG or rhythm strip, which results in angina, congestive heart failure, symptomatic hypotension, or requires treatment with a rate controlling drug, antiarrhythmic drug, or electrical cardioversion.
Measured: 30 days and 1 year after surgery
Nonfatal cardiac arrest
Successful resuscitation from either documented or presumed ventricular fibrillation, sustained ventricular tachycardia, asystole, or pulseless electrical activity requiring cardiopulmonary resuscitation, pharmacological therapy, or cardiac defibrillation.
Measured: 30 days and 1 year after surgery
Life-threatening bleeding
Life-threatening bleeding is bleeding that is fatal or leads to: significant hypotension that requires inotrope or vasopressor therapy, or urgent (within 24 hours) surgery (other than superficial vascular repair).
Measured: 30 days and 1 year after surgery
Critical organ bleeding
A critical organ bleeding event is bleeding that was intracranial, intraocular, intraspinal, pericardial, retroperitoneal, or intramuscular with compartment syndrome.
Measured: 30 days and 1 year after surgery
Peripheral arterial thrombosis
The investigators will consider a peripheral arterial thrombosis to have occurred where there is clear evidence of abrupt occlusion of a peripheral artery (i.e., not a stroke, myocardial infarction, or pulmonary embolism) consistent with either an acute local thrombotic event or a peripheral arterial embolism. To fulfill this definition, the investigators require at least one of the following objective findings of peripheral arterial thrombosis:
- Surgical report indicating evidence of arterial thrombosis/ peripheral arterial embolism;
- Pathological specimen demonstrating arterial thrombosis/ peripheral arterial embolism;
- Imaging evidence consistent with arterial thrombosis/ peripheral arterial embolism; or
- Autopsy reports documenting arterial thrombosis/ peripheral arterial embolism
Measured: 30 days and 1 year after surgery
Amputation
Any amputation procedure, or auto amputation after the initial surgery.
Measured: 30 days and 1 year after surgery
Delirium
For the diagnosis of delirium any one of the following criteria is required:
- Patient meets the criteria for delirium on any in-person delirium assessment based on the Confusion Assessment Method (CAM) or any of its operationalizations (e.g., 3D-CAM, CAM-ICU); OR
- Positive history of delirium based on the review of hospital health records.
Measured: 30 days and 1 year after surgery
Pneumonia
An acute infection of the pulmonary parenchyma that is associated with at least one sign or symptom of lower respiratory acute infection (e.g., cough, pleuritic chest pain) or acute systemic illness (e.g., fever, chills, confusion, hypoxemia); accompanied by the presence of an acute infiltrate/consolidation on a chest radiograph or auscultatory findings consistent with pneumonia (such as crackles and/or localized rales) for which there is no other explanation.
Measured: 30 days and 1 year after surgery
Surgical site infection
An infection that involves the skin, subcutaneous tissue of the incision (superficial incisional), or the deep soft tissue (e.g., fascia, muscle) of the incision (deep incisional).
Measured: 30 days and 1 year after surgery
Urinary tract infection
An infection that involves the urinary tract.
Measured: 30 days and 1 year after surgery
Clinically important ileus
Physician diagnosis of functional obstruction of the gastrointestinal tract in the absence of an alternative diagnosis that leads to postoperative decreased bowel activity. The definition requires the following criteria:
- inability to pass flatus or stool for >24 hours; and
- persistence of one or more of the following signs and symptoms for >24h (abdominal distention; diffuse abdominal pain; or nausea or vomiting.
Measured: 30 days and 1 year after surgery
Falls
Fall from standing height or walking
Measured: 30 days and 1 year after surgery
Post-discharge acute hospital care
A composite outcome of hospital re-admission and emergency department visit, which includes urgent-care centre visit.
Measured: 30 days after surgery
Emergency department visit
Visit to an emergency department, which includes urgent-care centre visits.
Measured: 30 days after surgery
Rehospitalization
Admission to acute care hospital after initial discharge from hospital for index surgery.
Measured: 30 days after surgery
Sepsis
The Third International Consensus Definitions Task Force defines sepsis as a "life-threatening organ dysfunction due to a dysregulated host response to infection." Based on the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) criteria, sepsis will require a quick Sequential Organ Failure Assessment (qSOFA) Score ≥2 points due to infection. The qSOFA includes the following items and scoring system:
- Glasgow Coma Scale (GCS) score of 13 or less (1 point),
- systolic blood pressure of 100 mm Hg or less (1 point), and
- respiratory rate of 22 breaths/min or more (1 point).
Measured: 1 year after surgery
Infection without sepsis
Pathologic process caused by the invasion of normally sterile tissue or fluid or body cavity by pathogenic or potentially pathogenic organisms.
Measured: 1 year after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Dec 2025
- Study startJun 2026 (estimated)
- Primary completionJun 2031 (estimated)
- Study completionJun 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myocardial Injury After Noncardiac Surgery (MINS)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 20,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hamilton Health Sciences Corporation
- Sponsor type
- University, hospital or other
- Collaborators
- McMaster University, Canadian Institutes of Health Research (CIHR), Population Health Research Institute
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07300579
- Sponsor's protocol ID
- 1.0.2026.01.13
- Acronym
- VISION-2
- Status last verified
- Apr 2026
- First submitted
- 10 Dec 2025
- Last updated
- 14 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Vascular Events in Noncardiac Surgery Patients Cohort Evaluation Study 2
- ClinicalTrials.gov ID
- NCT07300579
- Acronym / sponsor ID
- VISION-2 / 1.0.2026.01.13
- Conditions
- Myocardial Injury After Noncardiac Surgery (MINS), Bleeding Independently Associated With Mortality After Noncardiac Surgery (BIMS), Sepsis, Infection Without Sepsis, Post-operative Complications
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 20,000 participants (estimated)
- Lead sponsor
- Hamilton Health Sciences CorporationUniversity, hospital or other
- Collaborators
- McMaster University, Canadian Institutes of Health Research (CIHR), Population Health Research Institute
- Study start
- Jun 2026 (estimated)
- Primary completion
- Jun 2031 (estimated)
- Study completion
- Jun 2032 (estimated)
- First posted
- 24 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
VISION-2 is an international, multi-site, prospective observational cohort study of 20,000 patients undergoing noncardiac surgery. Continuous biometric data will be blindly collected for the first 30 postoperative days, in hospital and at home, using Vitaliti™. Following study enrollment and baseline data collection, follow up visits will occur in-hospital, at 30-days, and 1-year post-operatively.
VISION-2 has 3 primary objectives, among participants who underwent noncardiac surgery, the investigators will: 1) determine the pattern and frequency of physiological precursors (i.e., biophysical signals) to MINS, BIMS, sepsis, and infection without sepsis; 2) build prediction models from these biophysical signals and their extracted features through supervised machine learning, for the prediction and early detection of those complications; and 3) build a biobank for evaluation of novel biomarkers.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- Patients 65 years of age and older undergoing non-cardiac surgery with anesthesia expected to require an expected length of hospital stay of 3 or more days
Key inclusion criteria (3 listed)
- age ≥65 years;
- underwent non-cardiac surgery with general, neuraxial, local, or regional anesthesia; and
- expected length of hospital stay of 3 or more days
Key exclusion criteria (7 listed)
- hearing aid(s) or cochlear implant(s) in left ear;
- pacemaker/implantable cardioverter-defibrillator (ICD);
- externally programmable cerebrospinal fluid shunt;
- deep brain stimulator;
- intolerance/allergy to adhesive;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Continuous vital signs measurement deviceIn this observational study, enrolled participants will wear the Vitaliti™ CVSM-1A device continuously before surgery, wherever and whenever possible, or as soon as possible after surgery and for up to 30-days after surgery. We will collect continuous biometric data using the Vitaliti™ CVSM-1A device. Patients, healthcare providers, data collectors, and outcome adjudicators will be blind to the Vitaliti™ data. Data from participants will be analyzed to determine the pattern and frequency of physiological precursors to outcome events. This data will be used to inform machine learning algorithms for prediction and early detection of post-surgical complications. A biobank will also be established to support exploratory proteomic and genotyping analyses to better understand biological mechanisms underlying post-operative complications. | Device | – |
Primary outcome
Myocardial injury after noncardiac surgery (MINS)
Time frame: 30 days after surgery
MINS not meeting 4th definition of MI is an elevated troponin measurement that occurs during the first 30 days after surgery that is judged as resulting from myocardial ischemia AND does not fulfill the MI definition. The following defines elevated troponin measurement for the diagnosis of MINS during the first 30 days after surgery: non high sensitivity Troponin T assay: ≥0.03 µg/L; high sensitivity Troponin T assay: between 20 - <65 ng/L with an absolute change ≥5 ng/L or a value ≥65 ng/L; DVIA Centaur Siemens high-sensitivity cardiac troponin I: ≥75 ng/L; ARCHITECT STAT Abbott Laboratories high-sensitivity cardiac troponin I ≥60 ng/L; other troponin assays: any measurement above the 99th percentile of the upper reference limit.
Bleeding independently associated with mortality after noncardiac surgery (BIMS)
Time frame: 30 days after surgery
A bleeding meeting any of the following 3 criteria: a) leading to a postoperative hemoglobin <70 g/L; b) requiring transfusion of one or more units of red blood cells; c) judged to be the immediate cause of death
Sepsis
Time frame: 30 days after surgery
Based on the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) criteria, sepsis will require a quick Sequential Organ Failure Assessment (qSOFA) Score ≥2 points due to infection. The qSOFA includes the following items and scoring system: a) Glasgow Coma Scale (GCS) score of 13 or less (1 point); b) systolic blood pressure of 100 mm Hg or less (1 point); and c) respiratory rate of 22 breaths/min or more (1 point).
Infection without sepsis
Time frame: 30 days after surgery
Pathologic process caused by the invasion of normally sterile tissue or fluid or body cavity by pathogenic or potentially pathogenic organisms.
27 secondary outcomes
All-cause mortality
Time frame: 30 days after surgery
Vascular mortality
Time frame: 30 days and 1 year after surgery
Myocardial infarction (MI)
Time frame: 30 days and 1 year after surgery
Stroke
Time frame: 30 says and 1 year after surgery
Proximal venous thromboembolism (VTE)
Time frame: 30 days and 1 year after surgery
Proximal deep venous thrombosis (DVT)
Time frame: 30 days and 1 year after surgery
Pulmonary embolism (PE)
Time frame: 30 days and 1 year after surgery
Acute kidney injury (AKI)
Time frame: 30 days and 1 year after surgery
New acute renal failure resulting in dialysis
Time frame: 30 days and 1 year after surgery
Acute heart failure
Time frame: 30 days and 1 year after surgery
New clinically important atrial fibrillation
Time frame: 30 days and 1 year after surgery
Nonfatal cardiac arrest
Time frame: 30 days and 1 year after surgery
Life-threatening bleeding
Time frame: 30 days and 1 year after surgery
Critical organ bleeding
Time frame: 30 days and 1 year after surgery
Peripheral arterial thrombosis
Time frame: 30 days and 1 year after surgery
Amputation
Time frame: 30 days and 1 year after surgery
Delirium
Time frame: 30 days and 1 year after surgery
Pneumonia
Time frame: 30 days and 1 year after surgery
Surgical site infection
Time frame: 30 days and 1 year after surgery
Urinary tract infection
Time frame: 30 days and 1 year after surgery
Clinically important ileus
Time frame: 30 days and 1 year after surgery
Falls
Time frame: 30 days and 1 year after surgery
Post-discharge acute hospital care
Time frame: 30 days after surgery
Emergency department visit
Time frame: 30 days after surgery
Rehospitalization
Time frame: 30 days after surgery
Sepsis
Time frame: 1 year after surgery
Infection without sepsis
Time frame: 1 year after surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Myocardial Injury After Noncardiac Surgery (MINS)
RecruitingObservational study
Prediction Model for MINS After Major Hepatobiliary Surgery
Myocardial Injury After Noncardiac Surgery (MINS), Postoperative Complications
RecruitingPhase 4
The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery
Anesthesia, Surgery With General Anesthesia
Not yet recruitingPhase 4
Impact of Propranolol Strategies on Myocardial Injury After Breast Cancer Surgery
Breast Cancer, Myocardial Injury After Noncardiac Surgery (MINS)
Not yet recruiting
SecondarY Prevention and maNagement of Myocardial Injury aftER Noncardiac surGerY (SYNERGY) Pilot Trial
Myocardial Injury After Noncardiac Surgery (MINS)
RecruitingObservational study
Myocardial Injury After Noncardiac Surgery (MINS) in Lumbar Surgery Patients
MYOCARD INFARCTUS, Non Cardiac Surgery
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Myocardial Injury After Noncardiac Surgery (MINS) and Bleeding Independently Associated With Mortality After Noncardiac Surgery (BIMS), run by Hamilton Health Sciences Corporation at 3 sites in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 14 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Myocardial injury after noncardiac surgery (MINS) (time frame: 30 days after surgery). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Apr 2026.